Hidradenitis Suppurativa Associated with Adverse Cardiovascular Outcomes

Share this content:
The association between hidradenitis suppurativa and adverse CV outcomes warrants further research.
The association between hidradenitis suppurativa and adverse CV outcomes warrants further research.

(HealthDay News) — Hidradenitis suppurativa (HS) is independently associated with increased risk of adverse cardiovascular (CV) outcomes, according to a study published in JAMA Dermatology.

Alexander Egeberg, MD, PhD, from the University of Copenhagen in Denmark, and colleagues conducted a population-based study to examine CV risk in patients with HS. Data were included for 5964 patients aged 18 years or older with a hospital-based diagnosis of HS (cases) matched on age, sex, and calendar year with 29,404 controls.

The researchers found that the incidence rate ratios were 1.57 for myocardial infarction, 1.33 for ischemic stroke, 1.95 for CV-associated death, 1.53 for major adverse cardiovascular events (MACEs), and 1.35 for all-cause mortality, after adjustment for age, sex, socioeconomic status, smoking, comorbidity, and medication. Compared to patients with severe psoriasis, the adjusted incidence rates ratios were only significant for CV-associated death (adjusted incidence rate ratio, 1.58), but not for myocardial infarction, ischemic stroke, MACEs, and all-cause mortality.

"Hidradenitis suppurativa was associated with a significantly increased risk of adverse CV outcomes and all-cause mortality independent of measured confounders," the authors write. "The results call for increased awareness of this association and for studies of its clinical consequences."

Reference

  1. Egeberg A, Gislason GH, Hansen PR. Risk of Major Adverse Cardiovascular Events and All-Cause Mortality in Patients With Hidradenitis Suppurativa. JAMA Dermatol. 2016; doi: 10.1001/jamadermatol.2015.6264.
You must be a registered member of Endocrinology Advisor to post a comment.

Sign Up for Free e-Newsletters

CME Focus